Literature DB >> 22456329

Endostatin inhibits angiogenesis in hepatocellular carcinoma after transarterial chemoembolization.

Ying Bao1, Wen Ming Feng, Cheng Wu Tang, Yin Yuan Zheng, Hui Bin Gong, Er Gang Hou.   

Abstract

BACKGROUND/AIMS: This study aims to investigate the influence of endostatin on angiogenesis in hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE).
METHODOLOGY: Ninety-five patients with HCC were enrolled. Twenty-six patients received initial liver resection without preoperative TACE (non-TACE), 24 received preoperative TACE without endostatin (TACE), 22 received endostatin (15mg/m2) right after TACE intravenously (TACE-V) and 23 received endostatin (15mg/m2) through the hepatic artery during TACE (TACE-A). TACE was performed using Gemcitabine 1000mg/m2 (emulsified with lipiodol, 10-12mL), cisplatin 40 mg/m2 and 5-fluorouracil 500mg/m2 through the hepatic artery feeding the tumor. Patients received liver resection 4 weeks after second course of TACE.
RESULTS: The mean microvessel density (MVD) was 32.23±12.71, 57.46±18.38, 44.36±15.13 and 43.48±15.59 in non-TACE, TACE, TACE-V and TACE-A group respectively. The positive rate of vascular endothelial growth factor (VEGF) expression was 46.15%, 91.67%, 77.27% and 73.91% in non-TACE, TACE, TACE-V and TACE-A groups, respectively. Compared to the non-TACE group, MVD and VEGF expression in TACE, TACE-V and TACE-A groups were significantly higher (p<0.05). MVD and VEGF expression in the TACE-V and TACE-A groups were significantly lower than in the TACE group (p<0.05).
CONCLUSIONS: Endostatin could significantly repress angiogenesis in HCC after TACE by down-regulating expression of VEGF.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22456329     DOI: 10.5754/hge12138

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  10 in total

1.  Value of the portal venous phase in evaluation of treated hepatocellular carcinoma following transcatheter arterial chemoembolisation.

Authors:  A Lam; D Fernando; C C Sirlin; M Nayyar; S C Goodwin; D K Imagawa; C Lall
Journal:  Clin Radiol       Date:  2017-08-02       Impact factor: 2.350

2.  Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy.

Authors:  Haochen Wang; Weizhong Xiao; Yanjing Han; Shasha Cao; Zhiyuan Zhang; Guang Chen; Yuefeng Hu; Long Jin
Journal:  J Gastrointest Oncol       Date:  2022-06

3.  Adenovirus-mediated combined anti-angiogenic and pro-apoptotic gene therapy enhances antitumor efficacy in hepatocellular carcinoma.

Authors:  Fei Yan; Yi Zheng; Laiqiang Huang
Journal:  Oncol Lett       Date:  2012-10-23       Impact factor: 2.967

4.  Serum endostatin concentrations are higher in men with symptoms of intermittent claudication.

Authors:  Jonathan Golledge; Paula Clancy; Graeme J Hankey; Bu B Yeap; Paul E Norman
Journal:  Dis Markers       Date:  2014-01-30       Impact factor: 3.434

Review 5.  The Changes of HIF-1α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma.

Authors:  Kang Liu; Xu-Li Min; Juan Peng; Ke Yang; Lin Yang; Xiao-Ming Zhang
Journal:  J Clin Med Res       Date:  2016-02-27

6.  Systematic Review and Meta-analysis of Endostar Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone for Hepatocellular Carcinoma.

Authors:  Ya-Qing Zhang; Fei Zhao; Lei Song; Hong-Yun Gan; Xiao-Feng Xie
Journal:  J Evid Based Complementary Altern Med       Date:  2017-09-19

7.  Delisheng induces antiproliferation and apoptosis effects in Hep3B cells via modulation of angiogenic proteins.

Authors:  Hai-Feng Sun; Li Jing; Tao Wu; Ming Li; Ya-Huan Guo; Hui Guo; Zheng Zhao; Min-Cong Wang; Shu-Hong Wang; Ke-Jun Nan
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

8.  The Effect of GPX2 on the Prognosis of Lung Adenocarcinoma Diagnosis and Proliferation, Migration, and Epithelial Mesenchymal Transition.

Authors:  Yu-Peng Li; Rui Lin; Ming-Zhu Chang; Yi-Jiu Ai; Si-Ping Ye; Hui-Ming Han; Yao-Yue Zhang; Han Mou; Run-Hong Mu; Xiao Guo
Journal:  J Oncol       Date:  2022-07-18       Impact factor: 4.501

9.  The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.

Authors:  Fei-Xiang Wu; Jie Chen; Tao Bai; Shao-Liang Zhu; Tian-Bo Yang; Lu-Nan Qi; Ling Zou; Zi-Hui Li; Jia-Zhou Ye; Le-Qun Li
Journal:  BMC Cancer       Date:  2017-09-12       Impact factor: 4.430

10.  The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis.

Authors:  Zhoujing Cheng; Lin He; Yingjie Guo; Yuhua Song; Shasha Song; Lijiu Zhang
Journal:  World J Surg Oncol       Date:  2020-09-11       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.